Medication info

TR Duo Tablet 40/10 mg

Prescription medicationTabletOralApproval withdrawn
Ingredient · strength
Telmisartan›40mg / 1 tabletRosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Bionex Co., Ltd.
Appearance
Bright blue oval film-coated tablets
Packaging
30 tablets/box [10 tablets/PTP*3]
Approval status
Approval withdrawn

MFDS item code 201906977 · Approved 2019.09.30

This product's status changed to Approval withdrawn on 2024.08.22. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, prevention of cardiovascular disease, and inhibition of atherosclerosis progression
Who takes it
Adults
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. When this medicine is administered concomitantly with a thiazide diuretic such as hydrochlorothiazide, it has an additional blood pressure-lowering effect. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after the start of treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose is 80 mg of this medicine orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When initiating treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive medication may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams per day. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering this medicine at 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. For patients taking telmisartan and rosuvastatin concomitantly, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.

Ingredients

Manufacturer
Bionex Co., Ltd.

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, prevention of cardiovascular disease, and inhibition of atherosclerosis progression

  • Essential hypertension
  • coronary artery disease
  • peripheral arterial disease
  • stroke
  • transient ischemic attack
  • clinical evidence of end-organ damage
  • high-risk diabetes
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
View approved original text

This medication is used for patients who need to take both Telmisartan and Rosuvastatin simultaneously. Telmisartan helps treat hypertension and reduces the risk of myocardial infarction, stroke, and cardiovascular disease-related deaths in patients at high risk for heart disease. Rosuvastatin controls dyslipidemia such as hypercholesterolemia, slows the progression of atherosclerosis, and reduces the risk of developing cardiovascular diseases. It is particularly effective in reducing the risk of stroke and myocardial infarction in high-risk patients, as well as the risk of adverse effects after vascular interventions. By using these two medications together, it manages blood pressure and cholesterol, comprehensively improving the risk of cardiovascular diseases. Therefore, this medication is used for the prevention and management of cardiovascular diseases.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. When this medicine is administered concomitantly with a thiazide diuretic such as hydrochlorothiazide, it has an additional blood pressure-lowering effect. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after the start of treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose is 80 mg of this medicine orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When initiating treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive medication may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams per day. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering this medicine at 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. For patients taking telmisartan and rosuvastatin concomitantly, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.

Precautions

This medication can cause severe harm to the fetus and newborn, particularly during pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Women who are pregnant or may become pregnant, and nursing mothers should not use this medication, and fertile women not using appropriate contraception should be cautious. Patients with allergies to this medication or its components, severe liver impairment, biliary obstruction, active liver disease, myopathy, and patients with hereditary angioedema should not take this medication. Patients with significantly impaired renal function and those using certain drug combinations should also be advised against its use or proceed with caution. Elderly patients, those with hyperkalemia, mild to moderate liver impairment, cardiovascular disease, gastrointestinal disease, etc., should use this medication cautiously. Muscle-related adverse reactions such as myalgia, myopathy, and rhabdomyolysis may occur, so if muscle pain or weakness appears, one should consult a doctor immediately. This medication can affect liver function, so liver function tests are required before and during use, and if symptoms of liver dysfunction appear, administration should be stopped. Blood pressure may drop too low, so appropriate measures should be taken if symptoms of hypotension occur. This medication may interact with other drugs, so any other medications being taken should be reported to a doctor or pharmacist. Caution is needed when driving or operating machinery due to the possibility of dizziness or drowsiness. Store out of reach of children and avoid transferring to other containers.

Side effects

Headache, orthostatic dizziness, sleep paralysis, hypertension, hypotension, low blood pressure, increased ALT, dysuria, rhinitis, discomfort in the oropharynx, lung disease, unspecified gastrointestinal disease, benign gastrointestinal neoplasms, hemorrhoids, skeletal pain, osteoporosis, sensory impairment, movement disorders, atherosclerosis, frequency of urination, tinnitus, hearing loss, bad breath, fatty liver, upper respiratory infection, urinary tract infection, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reaction, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, syncope, visual disturbances, dizziness, bradycardia, tachycardia, dyspnea, abdominal pain, diarrhea, dyspepsia, abdominal distension, vomiting, abdominal discomfort, dry mouth, liver function abnormalities, liver disorders, increased sweating, itching, rash, erythema, angioedema, drug rash, toxic skin rash, eczema, urticaria, myalgia, lumbago, muscle cramps, arthralgia, limb pain, tendon pain, acute renal failure, chest pain, weakness, influenza-like illness, increased serum creatinine, increased serum uric acid, increased liver enzymes, elevated CK levels, decreased hemoglobin, facial spasms, sensory abnormalities, paralysis, cough, hyperventilation, pneumonia, flushing, erectile dysfunction, decreased appetite, arrhythmia, weakness, edema, decreased libido, facial edema, alopecia, conjunctivitis, tinnitus, petechiae, polyneuropathy, amnesia, peripheral neuropathy, constipation, pancreatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, ocular muscle weakness, headache, dizziness, constipation, nausea, abdominal pain, pruritus, myalgia, myopathy, rhabdomyolysis, weakness, increased ALT, chest pain, cough, myalgia, increased CK, dizziness, constipation, increased AST, weakness, joint pain, fatigue, numbness, sensory abnormalities, chest discomfort, nausea, abdominal pain, diarrhea, decreased appetite, abdominal distension, abnormal liver function tests, syncope, generalized pain, muscle cramps, gout, erectile dysfunction, arrhythmia, acute renal failure, oliguria, thrombocytopenia, increased serum creatinine, hypotension, tachycardia, bradycardia, dizziness, acute renal failure, hypoglycemia, weakness, hunger, cold sweats, tremors, decreased concentration, seizures, altered consciousness, angioedema, increased serum potassium, renal failure, shock, loss of consciousness, liver dysfunction, jaundice, anaphylactic-like symptoms, interstitial pneumonia, rhabdomyolysis, palpitations, fatigue, nausea, lack of effect

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is recommended to maintain a storage temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Bright blue oval film-coated tablets

Package unit

30 tablets/box [10 tablets/PTP*3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.